The end-to-end program is meant to help employees more seamlessly access and manage their GLP-1 prescriptions.

HLTH 2024 features high-profile panels, offline conversations, and chatter on buzzy topics like GLP-1 and health AI.

Noom Med with SmartRx, in partnership with Waltz Health, drives significant ROI for employers who wish to cover GLP-1s as a supplemental benefit ...

Noom is rolling out two new solutions that aim to make it easier for employers and members to manage GLP-1s, and it's teaming ...

Leveraging Waltz Connect by Waltz Health, the two industry leaders together are engineering a joint solution that will provide an end-to-end program that helps employees more seamlessly access and ...

Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help reduced the rate of overdoses and ...

Noom says the new scanning technology developed in partnership with Prism Labs will provide “actionable health insights”.

Recognizing women's unique health needs, Noom's Women’s Health features include content, tools, and a coach-led community ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

It has been a long time coming: The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity, along with other GLP-1 meds like Ozempic.